Literature DB >> 24446060

Characterization of antibody specificities associated with preeclampsia.

Serra E Elliott1, Nicholas F Parchim, Chen Liu, Yang Xia, Rodney E Kellems, Alex R Soffici, Patrick S Daugherty.   

Abstract

The presence of maternal autoantibodies has been previously associated with preeclampsia, although the composition of the antibody repertoire in preeclampsia has not been well characterized. Given this, we applied a bacterial display peptide library to identify peptides that preferentially react with plasma antibodies from patients with preeclampsia (n=15) versus healthy-outcome pregnancies (n=18). Screening using fluorescence-activated cell sorting identified 38 peptides that preferentially bind to antibodies from individuals with preeclampsia. These preeclampsia-specific peptides possessed similar motifs of R(G)/S(G)/-WW(G)/S, RWW(G)/S, or WGWGXX(R)/K distinct from the angiotensin II type 1 receptor epitope AFHYESQ. Seven library-isolated peptides and a cell surface-displayed angiotensin II type 1 receptor epitope were used to construct a diagnostic algorithm with a training set of 18 new preeclamptic and 22 healthy-outcome samples from geographically distinct cohorts. Cross-validation within the training group resulted in averaged areas underneath a receiver operating characteristic curve of 0.78 and 0.72 with and without the known receptor epitope, respectively. In a small validation set (12 preeclamptic; 8 healthy), the algorithm consisting only of library-isolated peptides correctly classified 10 preeclamptic and 6 healthy samples using a predefined cutoff that achieved 61% sensitivity (95% confidence interval, 36%-83%) at 95% specificity (95% confidence interval, 77%-100%) in training set (n=40) cross-validation. Our results indicate that antibodies with specificities other than anti-angiotensin II type 1 receptor are prevalent in preeclampsia patients and may be useful as diagnostic biomarkers.

Entities:  

Keywords:  antibodies; biological markers; diagnosis; peptide library; preeclampsia

Mesh:

Substances:

Year:  2014        PMID: 24446060      PMCID: PMC3984369          DOI: 10.1161/HYPERTENSIONAHA.113.02362

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

1.  Contemporary concepts of the pathogenesis and management of preeclampsia.

Authors:  Kristine Y Lain; James M Roberts
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

2.  Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension.

Authors:  Yu-Hua Liao; Yu-Miao Wei; Min Wang; Zhao-Hui Wang; Hai-Tao Yuan; Long-Xian Cheng
Journal:  Hypertens Res       Date:  2002-07       Impact factor: 3.872

3.  Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Authors:  Philip O Rabel; Christina B Planitzer; Maria R Farcet; Thomas R Kreil
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

4.  First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy.

Authors:  Francisco J Schneuer; Natasha Nassar; Cyrille Guilbert; Vitomir Tasevski; Anthony W Ashton; Jonathan M Morris; Christine L Roberts
Journal:  Pregnancy Hypertens       Date:  2013-05-16       Impact factor: 2.899

5.  Analysis of gene control signals by DNA fusion and cloning in Escherichia coli.

Authors:  M J Casadaban; S N Cohen
Journal:  J Mol Biol       Date:  1980-04       Impact factor: 5.469

6.  Anti-prothrombin antibodies are associated with adverse pregnancy outcome.

Authors:  Luca Marozio; Antonella Curti; Giovanni Botta; Emilie M Canuto; Loredana Salton; Anna Maria Tavella; Chiara Benedetto
Journal:  Am J Reprod Immunol       Date:  2011-06-20       Impact factor: 3.886

7.  Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature.

Authors:  Thomas Walther; Gerd Wallukat; Alexander Jank; Sabine Bartel; Heinz-Peter Schultheiss; Renaldo Faber; Holger Stepan
Journal:  Hypertension       Date:  2005-10-31       Impact factor: 10.190

8.  Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.

Authors:  Babbette LaMarca; Gerd Wallukat; Mayte Llinas; Florian Herse; Ralf Dechend; Joey P Granger
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

9.  Trophoblasts reduce the vascular smooth muscle cell proatherogenic response.

Authors:  Lydia Hering; Florian Herse; Stefan Verlohren; Joon-Keun Park; Maren Wellner; Fatimunnisa Qadri; Robert Pijnenborg; Anne C Staff; Berthold Huppertz; Dominik N Muller; Friedrich C Luft; Ralf Dechend
Journal:  Hypertension       Date:  2008-01-14       Impact factor: 10.190

10.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Authors:  Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi
Journal:  Circulation       Date:  2012-01-18       Impact factor: 29.690

View more
  9 in total

Review 1.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.

Authors:  Yariv Wine; Andrew P Horton; Gregory C Ippolito; George Georgiou
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

Review 2.  Preeclampsia and Pregnancy-Related Hypertensive Disorders.

Authors:  S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

3.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu M Madhavan; Martha Konieczkowski; Paul E Drawz; David B Thomas; Laura Barisoni; John R Sedor; John F O'Toole
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

Review 4.  Kidney disease and APOL1.

Authors:  Aminu Abba Yusuf; Melanie A Govender; Jean-Tristan Brandenburg; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

5.  Joint Associations of Maternal-Fetal APOL1 Genotypes and Maternal Country of Origin With Preeclampsia Risk.

Authors:  Xiumei Hong; Avi Z Rosenberg; Boyang Zhang; Elizabeth Binns-Roemer; Victor David; Yiming Lv; Rebecca C Hjorten; Kimberly J Reidy; Teresa K Chen; Guoying Wang; Yuelong Ji; Claire L Simpson; Robert L Davis; Jeffrey B Kopp; Xiaobin Wang; Cheryl A Winkler
Journal:  Am J Kidney Dis       Date:  2020-12-22       Impact factor: 11.072

6.  Association of preeclampsia with infant APOL1 genotype in African Americans.

Authors:  Anna K Miller; Timur Azhibekov; John F O'Toole; John R Sedor; Scott M Williams; Raymond W Redline; Leslie A Bruggeman
Journal:  BMC Med Genet       Date:  2020-05-20       Impact factor: 2.103

7.  Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry.

Authors:  Kimberly J Reidy; Rebecca C Hjorten; Claire L Simpson; Avi Z Rosenberg; Stacy D Rosenblum; Csaba P Kovesdy; Frances A Tylavsky; Joseph Myrie; Bianca L Ruiz; Soulin Haque; Khyobeni Mozhui; George W Nelson; Victor A David; Xiaoping Yang; Masako Suzuki; Jack Jacob; Sandra E Reznik; Frederick J Kaskel; Jeffrey B Kopp; Cheryl A Winkler; Robert L Davis
Journal:  Am J Hum Genet       Date:  2018-08-30       Impact factor: 11.025

8.  Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia.

Authors:  Chen Liu; Renna Luo; Serra E Elliott; Wei Wang; Nicholas F Parchim; Takayuki Iriyama; Patrick S Daugherty; Sean C Blackwell; Baha M Sibai; Rodney E Kellems; Yang Xia
Journal:  J Am Heart Assoc       Date:  2015-12-16       Impact factor: 5.501

9.  Transglutaminase is a Critical Link Between Inflammation and Hypertension.

Authors:  Renna Luo; Chen Liu; Serra E Elliott; Wei Wang; Nicholas Parchim; Takayuki Iriyama; Patrick S Daugherty; Lijian Tao; Holger K Eltzschig; Sean C Blackwell; Baha M Sibai; Rodney E Kellems; Yang Xia
Journal:  J Am Heart Assoc       Date:  2016-06-30       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.